-
Product Insights
Scape Living SA – 111-125 Anzac Parade Student Accommodation Tower – New South Wales
Equip yourself with the essential tools needed to make informed and profitable decisions with our Scape Living SA - 111-125 Anzac Parade Student Accommodation Tower - New South Wales report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the...
-
Product Insights
Scape – Leicester Street Student Accommodation Complex – Victoria
Equip yourself with the essential tools needed to make informed and profitable decisions with our Scape - Leicester Street Student Accommodation Complex - Victoria report. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? ·Unleash the full story: Dive...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ESB-1609
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry ESB-1609 Drug Details ESB-1609 is under development for the treatment of acid sphingomyelinase deficiency...
-
Product Insights
Parkinson’s Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Parkinson's disease (PD) is a neurodegenerative disorder characterized by movement dysfunctions. The main finding in brains of people with PD is loss of dopaminergic neurons in substantia nigra. Symptoms generally develop slowly over years. People with PD experience dyskinesia, dystonia, tremor, stiffness and impaired locomotory functions. Risk factors include age, genetic factors, environmental factors and gender. Treatment options include anticholinergics, COMT inhibitors and dopamine agonists. The Parkinson’s disease pipeline drugs market research report provides comprehensive information on the therapeutics under...
-
Company Insights
Meta Platforms, Inc – Digital Transformation Strategies
Meta Platforms Inc formerly Facebook, Inc. has been focusing on using augmented & virtual reality, data centers, artificial intelligence, blockchain, cybersecurity, and big data to digitally transform its operations. The annual ICT spending of Meta was estimated at $8.03 billion for 2021. A major share of this spending is earmarked for acquiring software, ICT services, and hardware from vendors. Meta is social networking, advertising, and business insight solutions provider that offers various products and services for commercial and non-commercial customers....
-
Product Insights
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C – Drugs In Development, 2022, provides an overview of the Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C (Genetic Disorders) pipeline landscape. Niemann-Pick C disease is one of a group of lysosomal storage diseases that affect metabolism and that are caused by genetic mutations. It involves the accumulation of sphingolipids in cells throughout the body, particularly reticuloendothelial cells (the mononuclear phagocyte system). Symptoms include...
-
Product Insights
Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Leucine-Rich Repeat Kinase 2 (LRRK2) is an enzyme encoded by the PARK8 gene. It plays a role in the retrograde trafficking pathway for recycling proteins, such as mannose 6 phosphate receptor (M6PR), between lysosomes and the Golgi apparatus in a retromer-dependent manner together with RAB29. It regulates neuronal process morphology in the intact central nervous system. The Leucine-Rich Repeat Kinase 2 - Drugs in Development research report provides a comprehensive overview on the therapeutics under development for Leucine-Rich Repeat Kinase...
-
Product Insights
Alzheimer’s Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Alzheimer’s Disease Drugs Development Report Overview Alzheimer's disease is a progressive, degenerative condition causing damage to memory and behavior due to the attack on the neurons. Predisposing factors include age, heredity, cardiovascular diseases or diabetes, and environmental factors. Symptoms include depression, anxiety, social withdrawal, irritability, and aggressiveness. Buy the Full Report for More Insights on the Alzheimer’s Disease Drugs in Development Report, Download a Free Sample The Alzheimer’s Disease Drugs in Development market research report provides an overview of the...
-
Sector Analysis
Global Luxury Fashion Goods Retailing to 2024 – Market Size, Forecast, Trends, and Competitive Landscape
This report provides an overview of the global luxury fashion retailing which includes key trends, key retail innovations, regional and sector analysis along with major luxury fashion retailers and competitive land scape In 2020, luxury fashion sales are estimated to fall by 12.6% to USD192.8 bn due to the COVID-19 crisis.
-
Product Insights
Gram-Negative Bacterial Infections Global Clinical Trials Review, H2, 2017
GlobalData's clinical trial report, “Gram-Negative Bacterial Infections Global Clinical Trials Review, H2, 2017" provides an overview of Gram-Negative Bacterial Infections clinical trials scenario. This report provides top line data relating to the clinical trials on Gram-Negative Bacterial Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...